Evenamide as an add-on to antipsychotics demonstrates significant efficacy in patients with schizophrenia in a potentially pivotal randomized placebo-controlled trial

Autor: Anand, R. ¹, Turolla, A. ², Chinellato, G. ², Giuliani, R. ², Sansi, F. ², Hartman, R. ³

Publikováno v: In Neuroscience Applied 2024 3 Supplement 2

Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.

Autor: Anand R; Anand Pharma Consulting (APC), St. Moritz, Switzerland., Turolla A; Newron Pharmaceuticals SpA, Bresso, Italy., Chinellato G; Newron Pharmaceuticals SpA, Bresso, Italy. Electronic address: giovanni.chinellato@newron.com., Sansi F; Newron Pharmaceuticals SpA, Bresso, Italy., Roy A; CliniRx Research Pvt Ltd, New Delhi, India., Hartman R; NeurWrite LLC, Morristown, NJ, USA.

Publikováno v: Neuropharmacology [Neuropharmacology] 2024 Dec 19; Vol. 266, pp. 110275. Date of Electronic Publication: 2024 Dec 19.